Valvular & structural heart diseaseSecondary analysis
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
- Post hoc analysis of the TRISCEND II randomised trial
- multicentre
- prospective
- randomized 2:1
- post hoc analysis stratified by baseline tricuspid regurgitation (TR) severity
Independent echocardiographic core laboratory, clinical events committee and data safety monitoring board
Authors' conclusion
Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.
Study context
- Population
- Patients with symptomatic, ≥severe TR, stratified into severe TR and massive/torrential TRstratified into severe TR 172 · massive/torrential TR 220
- Participants
- 400 patients
- Comparison
- Transcatheter tricuspid valve replacement (TTVR) plus medical therapy vs medical therapy alone
- TTVRn = 267
- Controln = 133reference
- Primary endpoint
- Primary safety and effectiveness endpoint (win ratio)
- Follow-up
- 1 year
Primary result
As reported in the abstract
Primary safety and effectiveness endpoint (win ratio), by baseline TR severity
TTVR vs ControlWin ratio (95% CI)
severe TR
1.64(1.11–2.43)
massive/torrential TR
2.20(1.55–3.14)
Further findings
| Outcome | rate difference (CI) | |
|---|---|---|
| All-cause mortality, by baseline TR severity · 18 months — TTVR vs Control · severe TR · Kaplan-Meier estimates | 0.2% (−11.6 to 11.9) | |
| All-cause mortality, by baseline TR severity · 18 months — TTVR vs Control · massive/torrential TR · Kaplan-Meier estimates | −5.8% (−17.6 to 6.0) | |
| HF hospitalization, by baseline TR severity · 18 months — TTVR vs Control · severe TR · Kaplan-Meier estimates | 9.8% (−3.0 to 22.7) | |
| HF hospitalization, by baseline TR severity · 18 months — TTVR vs Control · massive/torrential TR; favoured TTVR · Kaplan-Meier estimates | −15.2% (−28.9 to −1.5) | |
| −40−2002040Difference (linear scale) |
TR ≤mild after TTVR, by baseline TR severity · 1 year
- Severe TR
- 95.2%
- Massive/torrential TR
- 95.3%
All-cause mortality, by baseline TR severity · 18 months
- Similar mortality to controls
Original publication
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial. Eur Heart J. Published 29 August 2025. doi:10.1093/eurheartj/ehaf676
Summarised from the published abstract; every number is checked against it